Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2017

Study Completion Date

October 31, 2017

Conditions
Healthy MenMale ContraceptionHealthy WomenProduct Transference
Interventions
DRUG

Nestorone + Testosterone Combination Gel

The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).

Trial Locations (2)

90509

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

98195

University of Washington Medical Center & Health Sciences, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

collaborator

University of Washington

OTHER

collaborator

Population Council

OTHER

lead

Premier Research

OTHER

NCT02994602 - Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males | Biotech Hunter | Biotech Hunter